IQVIA HOLDINGS INC (QTS.DE) Fundamental Analysis & Valuation

FRA:QTS • US46266C1053

149.05 EUR
-5.3 (-3.43%)
Last: Mar 10, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This QTS.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to QTS. QTS was compared to 22 industry peers in the Life Sciences Tools & Services industry. While QTS is still in line with the averages on profitability rating, there are concerns on its financial health. QTS has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

5

1. QTS.DE Profitability Analysis

1.1 Basic Checks

  • In the past year QTS was profitable.
  • QTS had a positive operating cash flow in the past year.
  • Each year in the past 5 years QTS has been profitable.
  • In the past 5 years QTS always reported a positive cash flow from operatings.
QTS.DE Yearly Net Income VS EBIT VS OCF VS FCFQTS.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

1.2 Ratios

  • QTS has a Return On Assets (4.54%) which is in line with its industry peers.
  • Looking at the Return On Equity, with a value of 20.91%, QTS belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
  • The Return On Invested Capital of QTS (8.79%) is comparable to the rest of the industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for QTS is significantly below the industry average of 14.22%.
Industry RankSector Rank
ROA 4.54%
ROE 20.91%
ROIC 8.79%
ROA(3y)4.91%
ROA(5y)4.59%
ROE(3y)21.92%
ROE(5y)20.14%
ROIC(3y)8.91%
ROIC(5y)8.09%
QTS.DE Yearly ROA, ROE, ROICQTS.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20

1.3 Margins

  • QTS has a Profit Margin of 8.34%. This is comparable to the rest of the industry: QTS outperforms 45.45% of its industry peers.
  • QTS's Profit Margin has improved in the last couple of years.
  • QTS has a worse Operating Margin (14.02%) than 68.18% of its industry peers.
  • In the last couple of years the Operating Margin of QTS has grown nicely.
  • QTS has a worse Gross Margin (33.29%) than 68.18% of its industry peers.
  • QTS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 14.02%
PM (TTM) 8.34%
GM 33.29%
OM growth 3Y3.41%
OM growth 5Y15.26%
PM growth 3Y3.27%
PM growth 5Y27.69%
GM growth 3Y-1.55%
GM growth 5Y-0.4%
QTS.DE Yearly Profit, Operating, Gross MarginsQTS.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. QTS.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), QTS is destroying value.
  • The number of shares outstanding for QTS has been reduced compared to 1 year ago.
  • QTS has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, QTS has a worse debt to assets ratio.
QTS.DE Yearly Shares OutstandingQTS.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
QTS.DE Yearly Total Debt VS Total AssetsQTS.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • QTS has an Altman-Z score of 1.80. This is a bad value and indicates that QTS is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of QTS (1.80) is worse than 77.27% of its industry peers.
  • QTS has a debt to FCF ratio of 7.67. This is a slightly negative value and a sign of low solvency as QTS would need 7.67 years to pay back of all of its debts.
  • QTS has a Debt to FCF ratio (7.67) which is in line with its industry peers.
  • A Debt/Equity ratio of 2.14 is on the high side and indicates that QTS has dependencies on debt financing.
  • QTS has a Debt to Equity ratio of 2.14. This is amonst the worse of the industry: QTS underperforms 81.82% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.14
Debt/FCF 7.67
Altman-Z 1.8
ROIC/WACC0.85
WACC10.29%
QTS.DE Yearly LT Debt VS Equity VS FCFQTS.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

2.3 Liquidity

  • A Current Ratio of 0.75 indicates that QTS may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.75, QTS is doing worse than 86.36% of the companies in the same industry.
  • QTS has a Quick Ratio of 0.75. This is a bad value and indicates that QTS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.75, QTS is not doing good in the industry: 63.64% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.75
Quick Ratio 0.75
QTS.DE Yearly Current Assets VS Current LiabilitesQTS.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. QTS.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 7.09% over the past year.
  • QTS shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.19% yearly.
  • The Revenue has been growing slightly by 5.87% in the past year.
  • The Revenue has been growing slightly by 7.50% on average over the past years.
EPS 1Y (TTM)7.09%
EPS 3Y5.46%
EPS 5Y13.19%
EPS Q2Q%9.62%
Revenue 1Y (TTM)5.87%
Revenue growth 3Y4.21%
Revenue growth 5Y7.5%
Sales Q2Q%10.26%

3.2 Future

  • The Earnings Per Share is expected to grow by 10.27% on average over the next years. This is quite good.
  • QTS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.56% yearly.
EPS Next Y7.43%
EPS Next 2Y9.07%
EPS Next 3Y9.77%
EPS Next 5Y10.27%
Revenue Next Year6.49%
Revenue Next 2Y6.17%
Revenue Next 3Y6.17%
Revenue Next 5Y6.56%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
QTS.DE Yearly Revenue VS EstimatesQTS.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B 25B
QTS.DE Yearly EPS VS EstimatesQTS.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

5

4. QTS.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 14.43, which indicates a correct valuation of QTS.
  • Based on the Price/Earnings ratio, QTS is valued cheaper than 86.36% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 25.71. QTS is valued slightly cheaper when compared to this.
  • QTS is valuated correctly with a Price/Forward Earnings ratio of 13.43.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of QTS indicates a rather cheap valuation: QTS is cheaper than 90.91% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 23.82. QTS is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 14.43
Fwd PE 13.43
QTS.DE Price Earnings VS Forward Price EarningsQTS.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • 72.73% of the companies in the same industry are more expensive than QTS, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, QTS is valued cheaply inside the industry as 90.91% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 14.09
EV/EBITDA 12.33
QTS.DE Per share dataQTS.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 -50

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates QTS does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)1.94
PEG (5Y)1.09
EPS Next 2Y9.07%
EPS Next 3Y9.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. QTS.DE Dividend Analysis

5.1 Amount

  • QTS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

QTS.DE Fundamentals: All Metrics, Ratios and Statistics

IQVIA HOLDINGS INC

FRA:QTS (3/10/2026, 7:00:00 PM)

149.05

-5.3 (-3.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-05
Earnings (Next)05-04
Inst Owners102.12%
Inst Owner ChangeN/A
Ins Owners0.94%
Ins Owner ChangeN/A
Market Cap25.02B
Revenue(TTM)16.31B
Net Income(TTM)1.36B
Analysts82.67
Price Target223.17 (49.73%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-0.19%
Min EPS beat(2)-0.33%
Max EPS beat(2)-0.04%
EPS beat(4)2
Avg EPS beat(4)0.41%
Min EPS beat(4)-0.33%
Max EPS beat(4)1.56%
EPS beat(8)5
Avg EPS beat(8)0.54%
EPS beat(12)8
Avg EPS beat(12)0.59%
EPS beat(16)11
Avg EPS beat(16)0.76%
Revenue beat(2)1
Avg Revenue beat(2)0.75%
Min Revenue beat(2)-0.41%
Max Revenue beat(2)1.91%
Revenue beat(4)3
Avg Revenue beat(4)0.6%
Min Revenue beat(4)-0.41%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)0.19%
Revenue beat(12)5
Avg Revenue beat(12)0%
Revenue beat(16)6
Avg Revenue beat(16)-0.05%
PT rev (1m)0%
PT rev (3m)4.37%
EPS NQ rev (1m)-4.21%
EPS NQ rev (3m)-3.97%
EPS NY rev (1m)-2.04%
EPS NY rev (3m)-1.96%
Revenue NQ rev (1m)0.48%
Revenue NQ rev (3m)0.63%
Revenue NY rev (1m)0.99%
Revenue NY rev (3m)1.09%
Valuation
Industry RankSector Rank
PE 14.43
Fwd PE 13.43
P/S 1.77
P/FCF 14.09
P/OCF 10.89
P/B 4.44
P/tB N/A
EV/EBITDA 12.33
EPS(TTM)10.33
EY6.93%
EPS(NY)11.1
Fwd EY7.45%
FCF(TTM)10.58
FCFY7.1%
OCF(TTM)13.69
OCFY9.19%
SpS84.14
BVpS33.55
TBVpS-77.77
PEG (NY)1.94
PEG (5Y)1.09
Graham Number88.3
Profitability
Industry RankSector Rank
ROA 4.54%
ROE 20.91%
ROCE 10.59%
ROIC 8.79%
ROICexc 9.76%
ROICexgc N/A
OM 14.02%
PM (TTM) 8.34%
GM 33.29%
FCFM 12.58%
ROA(3y)4.91%
ROA(5y)4.59%
ROE(3y)21.92%
ROE(5y)20.14%
ROIC(3y)8.91%
ROIC(5y)8.09%
ROICexc(3y)9.78%
ROICexc(5y)8.82%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)10.72%
ROCE(5y)9.74%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y5.87%
ROICexc growth 5Y22.13%
OM growth 3Y3.41%
OM growth 5Y15.26%
PM growth 3Y3.27%
PM growth 5Y27.69%
GM growth 3Y-1.55%
GM growth 5Y-0.4%
F-Score5
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 2.14
Debt/FCF 7.67
Debt/EBITDA 4.05
Cap/Depr 52.71%
Cap/Sales 3.7%
Interest Coverage 3.53
Cash Conversion 77.35%
Profit Quality 150.81%
Current Ratio 0.75
Quick Ratio 0.75
Altman-Z 1.8
F-Score5
WACC10.29%
ROIC/WACC0.85
Cap/Depr(3y)54.81%
Cap/Depr(5y)54.94%
Cap/Sales(3y)3.98%
Cap/Sales(5y)4.25%
Profit Quality(3y)138.41%
Profit Quality(5y)159.78%
High Growth Momentum
Growth
EPS 1Y (TTM)7.09%
EPS 3Y5.46%
EPS 5Y13.19%
EPS Q2Q%9.62%
EPS Next Y7.43%
EPS Next 2Y9.07%
EPS Next 3Y9.77%
EPS Next 5Y10.27%
Revenue 1Y (TTM)5.87%
Revenue growth 3Y4.21%
Revenue growth 5Y7.5%
Sales Q2Q%10.26%
Revenue Next Year6.49%
Revenue Next 2Y6.17%
Revenue Next 3Y6.17%
Revenue Next 5Y6.56%
EBIT growth 1Y0.79%
EBIT growth 3Y7.77%
EBIT growth 5Y23.91%
EBIT Next Year27.21%
EBIT Next 3Y13.06%
EBIT Next 5Y11.23%
FCF growth 1Y-2.98%
FCF growth 3Y8.95%
FCF growth 5Y8.84%
OCF growth 1Y-2.28%
OCF growth 3Y5.5%
OCF growth 5Y6.26%

IQVIA HOLDINGS INC / QTS.DE FAQ

What is the ChartMill fundamental rating of IQVIA HOLDINGS INC (QTS.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to QTS.DE.


What is the valuation status for QTS stock?

ChartMill assigns a valuation rating of 5 / 10 to IQVIA HOLDINGS INC (QTS.DE). This can be considered as Fairly Valued.


What is the profitability of QTS stock?

IQVIA HOLDINGS INC (QTS.DE) has a profitability rating of 5 / 10.


How financially healthy is IQVIA HOLDINGS INC?

The financial health rating of IQVIA HOLDINGS INC (QTS.DE) is 1 / 10.


Is the dividend of IQVIA HOLDINGS INC sustainable?

The dividend rating of IQVIA HOLDINGS INC (QTS.DE) is 0 / 10 and the dividend payout ratio is 0%.